Sex Differences in RANTES (CCL5) in Patients With Intermediate Age-Related Macular Degeneration (AMD) and Controls With No AMD

Overview

Journal Transl Vis Sci Technol

Specialties Biomedical Engineering
Ophthalmology

Date 2022 Feb 8

PMID 35133404

Authors

Cheryl N Fonteh

Alan G Palestine

Brandie D Wagner

Jennifer L Patnaik

Marc T Mathias

Naresh Mandava

Rebecca Baldermann

Anne M Lynch

Affiliations

Soon will be listed here.

Abstract

Purpose: To determine if there are sex differences in levels of regulated upon activation, normal T cell expressed and secreted (RANTES) in patients with intermediate age-related macular degeneration (iAMD) and in controls with no AMD.

Methods: Patients with iAMD and controls defined by multi-modal imaging were recruited into a Colorado AMD registry. Plasma levels of the chemokine RANTES were measured using a multiplex assay. A nonparametric (rank-based) regression model was fit to RANTES with a sex by AMD category interaction.

Results: The plasma level of RANTES was significantly higher in the control group in comparison with the iAMD group. When moderated by sex, RANTES was significantly lower (P = 0.005) in males (median, 4525.6 pg/mL; interquartile range, 2589-7861 pg/mL) compared with females (median, 6686 pg/mL; interquartile range, 3485-12488 pg/mL) within the iAMD cohort. No significant difference was found in levels of RANTES between males and females in the control group.

Conclusions: We found that levels of RANTES were moderated by sex in cases with iAMD with lower levels in males compared with females. The findings illustrate the importance of including sex as a biological variable in AMD research. There is a need for further studies of RANTES, stratified by sex, in the advanced phenotypes of AMD.

Translational Relevance: The biomarker RANTES identified in the plasma of patients with iAMD reflects systemic alterations when stratified by sex.

Citing Articles

A Comprehensive Analysis of Sex-Biased Gene Expression in the Aging Human Retina Through a Combination of Single-Cell and Bulk RNA Sequencing.

Liu H, Zhang X, Wang Q, Li B, Bian B, Liu Y Invest Ophthalmol Vis Sci. 2025; 66(1):28.

PMID: 39804630 PMC: 11734759. DOI: 10.1167/iovs.66.1.28.

The Scavenging Activity of Coenzyme Q Plus a Nutritional Complex on Human Retinal Pigment Epithelial Cells.

Hernandez M, Recalde S, Bezunartea J, Moreno-Orduna M, Belza I, Chas-Prat A Int J Mol Sci. 2024; 25(15).

PMID: 39125641 PMC: 11311961. DOI: 10.3390/ijms25158070.

Elevated tumor necrosis factor alpha and vascular endothelial growth factor in intermediate age-related macular degeneration and geographic atrophy.

Rajeswaren V, Wagner B, Patnaik J, Mandava N, Mathias M, Manoharan N Front Ophthalmol (Lausanne). 2024; 4:1356957.

PMID: 38984140 PMC: 11182128. DOI: 10.3389/fopht.2024.1356957.

Association Between Quantitative and Qualitative Imaging Biomarkers and Geographic Atrophy Growth Rate.

de Carlo Forest T, Gill Z, Lisker-Cervantes A, Gnanaraj R, Grove N, Patnaik J Am J Ophthalmol. 2024; 264:168-177.

PMID: 38552931 PMC: 11257804. DOI: 10.1016/j.ajo.2024.03.023.

Interleukin-4 Plasma Levels Stratified by Sex in Intermediate Age-Related Macular Degeneration and Geographic Atrophy.

Rajeswaren V, Wagner B, Patnaik J, Mandava N, Mathias M, Manoharan N Transl Vis Sci Technol. 2023; 12(8):1.

PMID: 37526620 PMC: 10395651. DOI: 10.1167/tvst.12.8.1.

References

Fischer F, Luo Y, Luo M, Santambrogio L, Dorf M . RANTES-induced chemokine cascade in dendritic cells. J Immunol. 2001; 167(3):1637-43. DOI: 10.4049/jimmunol.167.3.1637. View

Ferris 3rd F, Wilkinson C, Bird A, Chakravarthy U, Chew E, Csaky K . Clinical classification of age-related macular degeneration. Ophthalmology. 2013; 120(4):844-51. PMC: 11551519. DOI: 10.1016/j.ophtha.2012.10.036. View

Fritsche L, Igl W, Cooke Bailey J, Grassmann F, Sengupta S, Bragg-Gresham J . A large genome-wide association study of age-related macular degeneration highlights contributions of rare and common variants. Nat Genet. 2015; 48(2):134-43. PMC: 4745342. DOI: 10.1038/ng.3448. View

Krogh Nielsen M, Subhi Y, Molbech C, Falk M, Nissen M, Sorensen T . Chemokine Profile and the Alterations in CCR5-CCL5 Axis in Geographic Atrophy Secondary to Age-Related Macular Degeneration. Invest Ophthalmol Vis Sci. 2020; 61(4):28. PMC: 7401724. DOI: 10.1167/iovs.61.4.28. View

. Risk factors associated with age-related macular degeneration. A case-control study in the age-related eye disease study: Age-Related Eye Disease Study Report Number 3. Ophthalmology. 2000; 107(12):2224-32. PMC: 1470467. DOI: 10.1016/s0161-6420(00)00409-7. View

Lambert N, Elshelmani H, Singh M, Mansergh F, Wride M, Padilla M . Risk factors and biomarkers of age-related macular degeneration. Prog Retin Eye Res. 2016; 54:64-102. PMC: 4992630. DOI: 10.1016/j.preteyeres.2016.04.003. View

Vladan B, Biljana S, Mandusic V, Zorana M, Zivkovic L . Instability in X chromosome inactivation patterns in AMD: a new risk factor?. Med Hypothesis Discov Innov Ophthalmol. 2014; 2(3):74-82. PMC: 3939760. View

Koper-Lenkiewicz O, Kaminska J, Lisowska A, Milewska A, Hirnle T, Dymicka-Piekarska V . Factors Associated with RANTES Concentration in Cardiovascular Disease Patients. Biomed Res Int. 2019; 2019:3026453. PMC: 6668548. DOI: 10.1155/2019/3026453. View

Testelmans D, Tamisier R, Barone-Rochette G, Baguet J, Roux-Lombard P, Pepin J . Profile of circulating cytokines: impact of OSA, obesity and acute cardiovascular events. Cytokine. 2013; 62(2):210-6. DOI: 10.1016/j.cyto.2013.02.021. View

10.

de Ferranti S, Rifai N . C-reactive protein and cardiovascular disease: a review of risk prediction and interventions. Clin Chim Acta. 2002; 317(1-2):1-15. DOI: 10.1016/s0009-8981(01)00797-5. View

11.

Palestine A, Wagner B, Patnaik J, Baldermann R, Mathias M, Mandava N . Plasma C-C Chemokine Concentrations in Intermediate Age-Related Macular Degeneration. Front Med (Lausanne). 2021; 8:710595. PMC: 8636771. DOI: 10.3389/fmed.2021.710595. View

12.

Sasaki M, Harada S, Kawasaki Y, Watanabe M, Ito H, Tanaka H . Gender-specific association of early age-related macular degeneration with systemic and genetic factors in a Japanese population. Sci Rep. 2018; 8(1):785. PMC: 5768785. DOI: 10.1038/s41598-017-18487-4. View

13.

Meleth A, Agron E, Chan C, Reed G, Arora K, Byrnes G . Serum inflammatory markers in diabetic retinopathy. Invest Ophthalmol Vis Sci. 2005; 46(11):4295-301. DOI: 10.1167/iovs.04-1057. View

14.

Shah D, Wanchu A, Bhatnagar A . Interaction between oxidative stress and chemokines: possible pathogenic role in systemic lupus erythematosus and rheumatoid arthritis. Immunobiology. 2011; 216(9):1010-7. DOI: 10.1016/j.imbio.2011.04.001. View

15.

Wagner B, Patnaik J, Palestine A, Frazer-Abel A, Baldermann R, Holers V . Association of Systemic Inflammatory Factors with Progression to Advanced Age-related Macular Degeneration. Ophthalmic Epidemiol. 2021; 29(2):139-148. PMC: 8497647. DOI: 10.1080/09286586.2021.1910314. View

16.

Lynch A, Patnaik J, Cathcart J, Mathias M, Siringo F, Echalier E . COLORADO AGE-RELATED MACULAR DEGENERATION REGISTRY: Design and Clinical Risk Factors of the Cohort. Retina. 2017; 39(4):656-663. DOI: 10.1097/IAE.0000000000002023. View

17.

Badacz R, Podolec J, Przewlocki T, Siedlinski M, Jozefczuk E, Oleksy H . The role of chemokine CCL5/RANTES and metalloproteinase-9 as inflammatory modulators in symptomatic internal carotid artery stenosis. J Physiol Pharmacol. 2019; 70(4). DOI: 10.26402/jpp.2019.4.06. View

18.

Pinto-Fraga J, Enriquez-de-Salamanca A, Calonge M, Gonzalez-Garcia M, Lopez-Miguel A, Lopez-de la Rosa A . Severity, therapeutic, and activity tear biomarkers in dry eye disease: An analysis from a phase III clinical trial. Ocul Surf. 2018; 16(3):368-376. DOI: 10.1016/j.jtos.2018.05.001. View

19.

Suffee N, Richard B, Hlawaty H, Oudar O, Charnaux N, Sutton A . Angiogenic properties of the chemokine RANTES/CCL5. Biochem Soc Trans. 2011; 39(6):1649-53. DOI: 10.1042/BST20110651. View

20.

Lynch A, Wagner B, Weiss S, Wall K, Palestine A, Mathias M . Proteomic Profiles in Advanced Age-Related Macular Degeneration Using an Aptamer-Based Proteomic Technology. Transl Vis Sci Technol. 2019; 8(1):14. PMC: 6348995. DOI: 10.1167/tvst.8.1.14. View